NEUP
Neuphoria Therapeutics Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$3.00
+0.33%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.00
From 52W high−45.26%
Volume47615.00
Market cap$16.23M
P/E (TTM)—
P/S (TTM)13.8x
Div yield—
Key dataNov 4, 2026
Open
$3.00
From 52W high
−45.26%
Volume
47615.00
Market cap
$16.23M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
26.7
MomentumView details →
1D Return
+0.33%
YTD Return
−22.16%
SummaryUpdated Jun 1, 2026
Neuphoria Therapeutics Inc. (NASDAQ:NEUP) is a clinical-stage biotechnology company founded on December 23, 2024, and headquartered in Burlington, Massachusetts. The company went public on December 16, 2021, and focuses on developing innovative therapies for individuals affected by neuropsychiatric disorders. As a relatively new entrant in the biotechnology sector, Neuphoria represents the emerging wave of specialized pharmaceutical companies targeting the complex intersection of neurology and psychiatry, an area that has historically been underserved by traditional drug development approaches.
Similar companies
Latest newsMore news →
Neuphoria Therapeutics amended its Rights Agreement with Computershare Trust Company, extending the agreement’s final expiration date to October 27, 2027.12d agoScancell Holdings plc announces an all-share merger to acquire Neuphoria Therapeutics Inc., with the combined company to operate as Scancell and trade on Nasdaq under the symbol SCLT.104d agoNeuphoria Therapeutics is in talks with Scancell Holdings plc about a possible combination.131d ago